IZIXATE 25 mg/0.50 ml, solution for injection in a pre-filled injector pen syringe, 0.50 ml
Active ingredients: Methotrexate
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 0.50 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IZIXATE 25 mg/0,50 mL, solution injectable en stylo injecteur prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue préremplie en verre de 0,50 mL avec aiguille dans un stylo injecteur
- Marketing authorisation holder
- ACCORD HEALTHCARE FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 May 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63815630CIP73024387CIP133400930243879Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉTHOTREXATEsolution | 25 mg · un stylo injecteur prérempli de 0,50 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.